These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 31289348)

  • 61. Tau mis-splicing correlates with motor impairments and striatal dysfunction in a model of tauopathy.
    Damianich A; Facal CL; Muñiz JA; Mininni C; Soiza-Reilly M; Ponce De León M; Urrutia L; Falasco G; Ferrario JE; Avale ME
    Brain; 2021 Sep; 144(8):2302-2309. PubMed ID: 34059893
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Inhibition of Calpain Protects Against Tauopathy in Transgenic P301S Tau Mice.
    Liu M; Wang L; Gao J; Dong Q; Perry G; Ma X; Wang X
    J Alzheimers Dis; 2019; 69(4):1077-1087. PubMed ID: 31156179
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Numb regulates Tau levels and prevents neurodegeneration in tauopathy mouse models.
    Lacomme M; Hales SC; Brown TW; Stevanovic K; Jolicoeur C; Cai J; Bois T; Desrosiers M; Dalkara D; Cayouette M
    Sci Adv; 2022 Oct; 8(42):eabm4295. PubMed ID: 36260685
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Inhibition of 2-Arachidonoylglycerol Metabolism Alleviates Neuropathology and Improves Cognitive Function in a Tau Mouse Model of Alzheimer's Disease.
    Hashem J; Hu M; Zhang J; Gao F; Chen C
    Mol Neurobiol; 2021 Aug; 58(8):4122-4133. PubMed ID: 33939165
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Phospho-Tau Accumulation and Structural Alterations of the Golgi Apparatus of Cortical Pyramidal Neurons in the P301S Tauopathy Mouse Model.
    Antón-Fernández A; Merchán-Rubira J; Avila J; Hernández F; DeFelipe J; Muñoz A
    J Alzheimers Dis; 2017; 60(2):651-661. PubMed ID: 28922155
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Animal models of tauopathies].
    Higuchi M
    Rinsho Shinkeigaku; 2006 Nov; 46(11):928-30. PubMed ID: 17432223
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Cornel Iridoid Glycoside Suppresses Hyperactivity Phenotype in rTg4510 Mice through Reducing Tau Pathology and Improving Synaptic Dysfunction.
    Ma DL; Luo Y; Huang R; Zhao ZR; Zhang L; Li YL; Wang Q; Li L; Zhang L
    Curr Med Sci; 2020 Dec; 40(6):1031-1039. PubMed ID: 33428130
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Accumulation of pathological tau species and memory loss in a conditional model of tauopathy.
    Berger Z; Roder H; Hanna A; Carlson A; Rangachari V; Yue M; Wszolek Z; Ashe K; Knight J; Dickson D; Andorfer C; Rosenberry TL; Lewis J; Hutton M; Janus C
    J Neurosci; 2007 Apr; 27(14):3650-62. PubMed ID: 17409229
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles.
    Castillo-Carranza DL; Sengupta U; Guerrero-Muñoz MJ; Lasagna-Reeves CA; Gerson JE; Singh G; Estes DM; Barrett AD; Dineley KT; Jackson GR; Kayed R
    J Neurosci; 2014 Mar; 34(12):4260-72. PubMed ID: 24647946
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Invited review: Neuropathology of tauopathies: principles and practice.
    Kovacs GG
    Neuropathol Appl Neurobiol; 2015 Feb; 41(1):3-23. PubMed ID: 25495175
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Modulation of Tau Isoforms Imbalance Precludes Tau Pathology and Cognitive Decline in a Mouse Model of Tauopathy.
    Espíndola SL; Damianich A; Alvarez RJ; Sartor M; Belforte JE; Ferrario JE; Gallo JM; Avale ME
    Cell Rep; 2018 Apr; 23(3):709-715. PubMed ID: 29669277
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Microglial activation arises after aggregation of phosphorylated-tau in a neuron-specific P301S tauopathy mouse model.
    van Olst L; Verhaege D; Franssen M; Kamermans A; Roucourt B; Carmans S; Ytebrouck E; van der Pol SMA; Wever D; Popovic M; Vandenbroucke RE; Sobrino T; Schouten M; de Vries HE
    Neurobiol Aging; 2020 May; 89():89-98. PubMed ID: 32008854
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Novel Key Players in the Development of Tau Neuropathology: Focus on the 5-Lipoxygenase.
    Lauretti E; Praticò D
    J Alzheimers Dis; 2018; 64(s1):S481-S489. PubMed ID: 29758943
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Elevated levels of brain homocysteine directly modulate the pathological phenotype of a mouse model of tauopathy.
    Di Meco A; Li JG; Barrero C; Merali S; Praticò D
    Mol Psychiatry; 2019 Nov; 24(11):1696-1706. PubMed ID: 29728702
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Neuronal
    Sargent D; Cunningham LA; Dues DJ; Ma Y; Kordich JJ; Mercado G; Brundin P; Cowell RM; Moore DJ
    Brain Commun; 2021; 3(3):fcab208. PubMed ID: 34704029
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Formation of retromer transport carriers is disrupted by the Parkinson disease-linked Vps35 D620N variant.
    Cui Y; Yang Z; Flores-Rodriguez N; Follett J; Ariotti N; Wall AA; Parton RG; Teasdale RD
    Traffic; 2021 Apr; 22(4):123-136. PubMed ID: 33347683
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Sustained Arginase 1 Expression Modulates Pathological Tau Deposits in a Mouse Model of Tauopathy.
    Hunt JB; Nash KR; Placides D; Moran P; Selenica ML; Abuqalbeen F; Ratnasamy K; Slouha N; Rodriguez-Ospina S; Savlia M; Ranaweera Y; Reid P; Dickey CA; Uricia R; Yang CG; Sandusky LA; Gordon MN; Morgan D; Lee DC
    J Neurosci; 2015 Nov; 35(44):14842-60. PubMed ID: 26538654
    [TBL] [Abstract][Full Text] [Related]  

  • 78. VPS35 pathogenic mutations confer no dominant toxicity but partial loss of function in Drosophila and genetically interact with parkin.
    Malik BR; Godena VK; Whitworth AJ
    Hum Mol Genet; 2015 Nov; 24(21):6106-17. PubMed ID: 26251041
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The Parkinson's disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human.
    Mir R; Tonelli F; Lis P; Macartney T; Polinski NK; Martinez TN; Chou MY; Howden AJM; König T; Hotzy C; Milenkovic I; Brücke T; Zimprich A; Sammler E; Alessi DR
    Biochem J; 2018 Jun; 475(11):1861-1883. PubMed ID: 29743203
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Selective suppression of the α isoform of p38 MAPK rescues late-stage tau pathology.
    Maphis N; Jiang S; Xu G; Kokiko-Cochran ON; Roy SM; Van Eldik LJ; Watterson DM; Lamb BT; Bhaskar K
    Alzheimers Res Ther; 2016 Dec; 8(1):54. PubMed ID: 27974048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.